

## Company Overview

Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the point of care (POCare) to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all.

## Orgenesis CEO Vered Caplan Provides Letter to Shareholders

Mar 30 2020, 7:30 AM EDT

## Stock Overview

Symbol	ORGS
Exchange	Nasdaq
Market Cap	60.78m
Last Price	\$3.31
52-Week Range	\$2.35 - \$6.4888

03/30/2020 04:00 PM EDT

## Investor Relations

Crescendo Communications, LLC  
David K. Waldman  
T: (212) 671-1020  
[orgs@crescendo-ir.com](mailto:orgs@crescendo-ir.com)

## Management Team

### Vered Caplan

President, Chief Executive Officer and Director

### Neil Reithinger, CPA

Chief Financial Officer, Secretary, and Treasurer

### Frédéric Tonglet

General Manager, Orgenesis, Belgium

### Evan Fishman

Chief Financial Officer, Orgenesis LTD

### Peter Molloy

Executive Vice President, Corporate Development

---

## Orgenesis Inc.

Orgenesis Inc. (Corporate Headquarters)  
20271 Goldenrod Lane  
Germantown, MD 20876  
USA

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.